Sanofi
SAN
Rank in Stocks
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Share Price
$83.84
Market Cap
$100.45B
Change (1 day)
1.48%
Change (1 year)
-16.74%
Country
FR
Trade Sanofi (SAN)
Category
Healthcare
Operating Margin for Sanofi (SAN)
Operating Margin as of October 2026 TTM: 20.58%
According to Sanofi latest financial reports and stock price the company's current Operating Margin (TTM) is 20.58%. At the end of 2024 the company had an Operating Margin of 32.63%.
Operating Margin history for Sanofi from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 20.58% | 0.19% |
| 2025 | 20.54% | -37.05% |
| 2024 | 32.63% | 3.36% |
| 2023 | 31.57% | -3.22% |
| 2022 | 32.62% | 57.28% |
| 2021 | 20.74% | -45.09% |
| 2020 | 37.77% | 365.72% |
| 2019 | 8.11% | -38.14% |
| 2018 | 13.11% | -18.16% |
| 2017 | 16.02% | -14.88% |
| 2016 | 18.82% | 16.68% |
| 2015 | 16.13% | -14.88% |
| 2014 | 18.95% | 19.03% |
| 2013 | 15.92% | -28.19% |
| 2012 | 22.17% | 35.60% |
| 2011 | 16.35% | -12.14% |
| 2010 | 18.61% | -10.10% |
| 2009 | 20.70% | -38.90% |
| 2008 | 33.88% | 67.39% |
| 2007 | 20.24% | 4.17% |
| 2006 | 19.43% | -25.64% |
| 2005 | 26.13% | -1,593.14% |
| 2004 | -1.75% | -104.58% |
| 2003 | 38.21% | 8.89% |
| 2002 | 35.09% | 8.10% |
| 2001 | 32.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 49.72% | -97.58% |
US
|
|
| 25.70% | -98.75% |
US
|
|
| 29.32% | -98.58% |
US
|
|
| 16.65% | -99.19% |
US
|
|
| 31.92% | -98.45% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.